Insulet (PODD) Change in Accured Expenses (2010 - 2026)
Insulet (PODD) posted Change in Accured Expenses of -$69.3 million for Q1 2026, down 142.96% on a QoQ basis from $161.3 million in Q4 2025, and down 42.59% year-over-year from -$120.7 million in Q1 2025.
Insulet (PODD) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Insulet's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$69.3 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 42.59% year-over-year to -$69.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.5 million (up 2281.36% YoY) and the FY2025 annual result came in at $161.2 million, up 2140.51% from the prior year.
- Change in Accured Expenses was -$69.3 million for Q1 2026 at Insulet, down from $161.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $161.3 million in Q4 2025 and bottomed at -$69.3 million in Q1 2026.
- A 5-year average of $12.6 million and a median of -$4.2 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 12033.33% — and 2025, when it jumped 1954.02%.
- Insulet's Change in Accured Expenses stood at $132.1 million in 2022, then plunged by 103.18% to -$4.2 million in 2023, then plunged by 107.14% to -$8.7 million in 2024, then soared by 1954.02% to $161.3 million in 2025, then tumbled by 142.96% to -$69.3 million in 2026.
- Business Quant data shows PODD's Change in Accured Expenses at -$69.3 million in Q1 2026, $161.3 million in Q4 2025, and $900000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 145.10 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -250.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 21.07 Mn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | -69.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.30 Mn |
| Mar 31, 2026 | -69.30 Mn |
| Dec 31, 2025 | 161.30 Mn |
| Dec 31, 2025 | 161.30 Mn |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 47.60 Mn |
| Jun 30, 2025 | 47.60 Mn |
| Mar 31, 2025 | -48.60 Mn |
| Mar 31, 2025 | -48.60 Mn |
| Dec 31, 2024 | -8.70 Mn |
| Dec 31, 2024 | -8.70 Mn |
| Sep 30, 2024 | -7.40 Mn |
| Sep 30, 2024 | -7.40 Mn |
| Jun 30, 2024 | 70.60 Mn |
| Jun 30, 2024 | 70.60 Mn |
| Mar 31, 2024 | -62.40 Mn |
| Mar 31, 2024 | -62.40 Mn |
| Dec 31, 2023 | -4.20 Mn |
| Dec 31, 2023 | -4.20 Mn |